2'-Hydroxyflavanone: A promising molecule for kidney cancer prevention

Area of Science:

• Oncology
• Chemoprevention
• Plant-derived compounds

Background:

• Renal cell carcinoma (RCC) is a rising cancer diagnosis in the USA.
• RCC exhibits high resistance to chemotherapy and radiation, limiting treatment options.
• VHL gene mutations, often linked to smoking, are a frequent cause of RCC.

Purpose of the Study:

• To review the potential of 2 extquotesingle-hydroxyflavanone, a citrus-derived compound, as a chemoprevention strategy for kidney cancer.
• To explore the mechanisms by which 2 extquotesingle-hydroxyflavanone may counteract VHL gene mutations and inhibit RCC progression.

Main Methods:

• Review of in vitro and preclinical mouse studies on 2 extquotesingle-hydroxyflavanone.
• Analysis of the compound's effect on VHL locus protection and VHL-mutant cancer progression.

Main Results:

• In vitro and preclinical studies indicate 2 extquotesingle-hydroxyflavanone can protect the VHL locus.
• The compound demonstrated potential in preventing the progression of VHL-mutant kidney cancer in preclinical models.

Conclusions:

• 2 extquotesingle-hydroxyflavanone presents considerable potential as an agent for kidney cancer chemoprevention.
• Plant-derived compounds like 2 extquotesingle-hydroxyflavanone offer a novel strategy against highly resistant renal cell carcinoma.